Abstract
Interleukin-2 (IL-2) is now registered for the treatment of renal cell carcinoma in a number of European countries. The subcutaneous (sc) route of administration is being used increasingly because of its better toxicity profile compared with higher dose intravenous (iv) protocols. We report here a patient who developed a lobular panniculitis at the site of sc IL-2 injection which prevents continuation of sc therapy. Subsequent administration of the same IL-2 dose by iv injection caused recurrence of the problem again necessitating discontinuation of IL-2 treatment.
Highlights
Sporadic cases of IL-2 associated erythema nodosum, fatal pemphigus vulgaris (IL-2 + Interferon-a) and life threatening bullous skin lesions (IL-2, concomitant administration of antibiotics) have been reported (Weinstein et al, 1987; Mier et al, 1988; Ramseur et al, 1989; Staunton et al, 1991)
We report here a patient who developed a lobular panniculitis at the site of sc IL-2 injection which prevents continuation of sc therapy
One of the observed sideeffects was local irritation with redness and swelling at the IL-2 injection sites, which has been reported to be tolerable to the patients (Atzpodien et al, 1990)
Summary
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
